Fructose and fructose kinase in cancer and other pathologies  

作　　者：Hongfei Jiang Qian Lin Leina Ma Shudi Luo Xiaoming Jiang Jing Fang Zhimin Lu 

机构地区：[1]Cancer Institute of The Affiliated Hospital of Qingdao University and Qingdao Cancer Institute,Qingdao 266061,China [2]Zhejiang Provincial Key Laboratory of Pancreatic Disease,The First Affiliated Hospital,Institute of Translational Medicine,Zhejiang University School of Medicine,Hangzhou 310029,China [3]Zhejiang University Cancer Center,Hangzhou 310029,China

出　　处：《Journal of Genetics and Genomics》2021年第7期531-539,共9页遗传学报（英文版）

基　　金：supported by grants from the Ministry of Science and Technology of the People’s Republic of China(2020YFA0803300 to Z.L.,J.F.);the National Natural Science Foundation of China(82030074,Z.L.;82073061,J.F.;81672926,L.M.);the Zhejiang Natural Science Foundation-Key Project(LD21H160003,Z.L.);the Zhejiang University Research Fund(188020*194221901/029,Z.L.);the Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang(2019R01001,Z.L.)。

摘　　要：Fructose metabolism and fructose kinase KHKe C/A are key factors in the development of lipid oversynthesis-promoted metabolic disorders and cancer.Here,we summarize and discuss the current knowledge about the specific features of fructose metabolism and the distinct roles of KHKe C and KHKe A in metabolic liver diseases and their relevant metabolic disorders and cancer,and we highlight the specific protein kinase activity of KHKe A in tumor development.In addition,different approaches that have been used to inhibit KHK and the exploration of KHK inhibitors in clinical treatment are introduced.

关 键 词：FRUCTOSE GLUCOSE KHKe-C KHK-A CANCER NAFLD NASH Metabolic disorders 

分 类 号：R730.2[医药卫生—肿瘤]